A New Method for Finding Molecular Glues Snags an Elusive Diabetes Target
A new approach to "molecular glue" drug design snags an "undruggable" diabetes target.
A new approach to "molecular glue" drug design snags an "undruggable" diabetes target.
An international grant to Thomas Kodadek, Ph.D., will advance his lab’s work on molecular glue degraders for incurable diseases.
Compounds able to reprogram insulin-resistant cells into a healthier state, with reduced side effects, are described in a new paper from Griffin lab.
Wertheim Fellow, “Tony” Kuang-Ting Kuo, is in the final year of his Ph.D. program in the lab of Scientific Director Patrick Griffin, Ph.D. He recently co-mentored high school student intern Shivangi Saxena. In 2022, Dr. Herbert Wertheim made a transformational $100 million gift to The Herbert Wertheim UF Scripps…
Altering the activity of the PPARg receptor could limit the side-effects of a useful group of diabetes drugs, TZDs.